2,068 items · By date added

Bernstein: China’s innovative drugs gain global clinical validation: Kelun and Hansoh report strong data, while Innovent’s first-line lung cancer treatment remains under scrutiny

Bernstein believes the key change at ESMO 2026 was that several drugs developed in China produced efficacy data in global studies. Kelun-Biotech achieved a positive global phase III result, while Hansoh’s early data sustained the efficacy seen in China; Innovent’s IBI363 faces tests of efficacy durability and safety.

Fred Hu: Is Weak A-Share Sentiment an Opportunity or a Reason to Stay Away?

Primavera Capital founder Fred Hu discusses Chinese equities on Bloomberg’s The China Show: Near-term uncertainty and weak consumption coexist with strengths in manufacturing efficiency, exports and energy resilience. Opportunities and risks should be considered separately.

Goldman Sachs: Weichai Power: Data-center power generation’s share of profit rises to thirty percent, while gas-generator sets have yet to ramp up to take over

In the third quarter of 2026, data-center power generation offset weakness in traditional businesses and foreign-exchange pressure, driving Weichai Power’s EBIT to a record high. Goldman Sachs expects gas-generator sets to drive profit growth in 2027, but prioritizing diesel-engine capacity could push back some gas-generator deliveries.

Goldman Sachs: Goldman Sachs raises oil price forecasts: Supply disruption risks lift premium, but prices still expected to fall in 2027

Goldman Sachs raised its forecast for the average Brent crude price in 2027 from $80 to $88 per barrel and added an allowance for disruptions of 1 million barrels per day to its supply model. The bank believes the recent rise in oil prices has been driven mainly by a risk premium, while supply and demand adjustments have brought the global market back into balance.